BioSyent Pharma Inc. Signs Exclusive Product Development, Supply and Distribution Agreement
Published: Sep 01, 2009
MISSISSAUGA, ONTARIO--(Marketwire - August 31, 2009) - BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division. The product will be launched after Health Canada approval. This agreement represents the second new partner, with whom BioSyent Pharma has signed an agreement in the last two months.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Rene C. Goehrum
President and CEO
(905) 206-1413 (FAX)